A Phase 1, Multi-center, Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease; Multiple sclerosis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 31 Jan 2019 Status changed from recruiting to completed.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 19 Sep 2018 New trial record